NASDAQ:ARTL Artelo Biosciences (ARTL) Stock Price, News & Analysis $3.63 +0.12 (+3.42%) As of 10:14 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsSEC Filings About Artelo Biosciences Stock (NASDAQ:ARTL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Artelo Biosciences alerts:Sign Up Key Stats Today's Range$3.58▼$3.7450-Day Range$3.51▼$7.9252-Week Range$3.45▼$179.19Volume13,504 shsAverage Volume323,337 shsMarket Capitalization$1.99 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a network of receptors and signaling pathways involved in processes such as pain, inflammation, appetite and immune response. The company is headquartered in San Diego, California, and its research and development activities are directed toward pharmaceutical applications of cannabinoid biology rather than consumer cannabis products. Artelo’s pipeline has included ART27.13, a peripherally restricted cannabinoid receptor agonist being evaluated for conditions associated with appetite loss and cancer-related cachexia. The company has also developed ART12.11, a proprietary cannabidiol-based cocrystal intended for potential use in oncology, including glioblastoma, and ART26.12, a fatty acid amide hydrolase inhibitor being investigated for pain and cancer-related applications. Development programs and indications may change as clinical and regulatory work progresses. The company was established to advance cannabinoid-based medicines through preclinical and clinical development and has worked with academic and commercial partners to support its programs. Artelo Biosciences is led by President and Chief Executive Officer Gregory D. Gorgas. Its therapeutic programs are intended for international pharmaceutical markets, although the company’s principal operations and corporate base are in the United States.AI Generated. May Contain Errors. Read More Artelo Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreARTL MarketRank™: Artelo Biosciences scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingArtelo Biosciences has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageArtelo Biosciences has only been the subject of 1 research reports in the past 90 days.Read more about Artelo Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Artelo Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artelo Biosciences is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Artelo Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.25% of the float of Artelo Biosciences has been sold short.Short Interest Ratio / Days to CoverArtelo Biosciences has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Artelo Biosciences has recently decreased by 37.22%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtelo Biosciences does not currently pay a dividend.Dividend GrowthArtelo Biosciences does not have a long track record of dividend growth. News and Social Media3.9 / 5News SentimentN/A News SentimentArtelo Biosciences has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Artelo Biosciences this week, compared to 3 articles on an average week.Search Interest4 people have searched for ARTL on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Artelo Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Artelo Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.20% of the stock of Artelo Biosciences is held by insiders.Percentage Held by Institutions0.87% of the stock of Artelo Biosciences is held by institutions.Read more about Artelo Biosciences' insider trading history. Receive ARTL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARTL Stock News HeadlinesArtelo Biosciences, Inc. (NASDAQ:ARTL) Shares Shorted: Short Interest Down 37.2% in SeptemberOctober 1, 2026 | americanbankingnews.comArtelo Biosciences (ARTL)September 23, 2026 | es.investing.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.October 6 at 1:00 AM | Profits Run (Ad)Artelo Expands ART27.13 Patent Coverage After Obesity Study FindingsSeptember 23, 2026 | rttnews.comArtelo Biosciences (ARTL) Stock Surges Wednesday: What's Happening?September 23, 2026 | benzinga.comArtelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected ...September 23, 2026 | finance.yahoo.comArtelo Biosciences Files New Provisional Patent Application Covering ART27.13 for Obesity, Alone and in Combination with GLP-1 Receptor Agonists, Following Unexpected Nonclinical FindingsSeptember 23, 2026 | globenewswire.comArtelo Reports ART27.13 Matches Semaglutide Weight Loss In Obesity ModelSeptember 16, 2026 | rttnews.comSee More Headlines ARTL Stock Analysis - Frequently Asked Questions How have ARTL shares performed this year? Artelo Biosciences' stock was trading at $32.94 at the start of the year. Since then, ARTL stock has decreased by 89.3% and is now trading at $3.51. How were Artelo Biosciences' earnings last quarter? Artelo Biosciences, Inc. (NASDAQ:ARTL) issued its quarterly earnings data on Wednesday, August, 12th. The company reported ($0.89) EPS for the quarter, topping the consensus estimate of ($6.48) by $5.59. When did Artelo Biosciences' stock split? Artelo Biosciences's stock reverse split on Tuesday, March 10th 2026.The 1-3 reverse split was announced on Friday, March 6th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Monday, March 9th 2026. An investor that had 100 shares of stock prior to the reverse split would have 33 shares after the split. When did Artelo Biosciences IPO? Artelo Biosciences (ARTL) raised $80,000 in an initial public offering (IPO) on Friday, June 21st 2019. The company issued 8,000,000 shares at a price of $0.01 per share. How do I buy shares of Artelo Biosciences? Shares of ARTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Artelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artelo Biosciences investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/12/2026Today10/06/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ARTL's financial health is in the Red zone, according to TradeSmith. ARTL has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ARTL CIK1621221 Webwww.artelobio.com Phone(858) 925-7049FaxN/AEmployees7Year Founded2017Profitability EPS (Trailing Twelve Months)($151.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.88 million Net MarginsN/A Pretax MarginN/A Return on Equity-518.27% Return on Assets-194.29% Debt Debt-to-Equity RatioN/A Current Ratio3.00 Quick Ratio3.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($17.03) per share Price / Book-0.21Miscellaneous Outstanding Shares548,000Free Float530,000Market Cap$1.99 million OptionableNot Optionable Beta-0.07 Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:ARTL) was last updated on 10/6/2026 by MarketBeat.com Staff. From Our PartnersA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredThe case for $20,000 gold before year endPresident Trump reposted a warning from precious metals expert Jim Rickards, tying the November midterms and A...Stansberry Research | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Mid-Term Meltdown”In 2016, major election models gave Hillary Clinton a 99% chance of winning - but former CIA and Pentagon advi...Paradigm Press | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredAnthropic’s $40 million midterm moveAnthropic, creator of Claude, has committed $40 million to Public First Action, a nonpartisan group advocating...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artelo Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
